Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• The phosphoinositide 3-kinase (PI3K)-Akt-mTOR pathway is frequently deregulated in human cancers.
• Akt activation is critical for cancer cell survival and oncogenesis.
• Targeting the interaction between Akt's pleckstrin homology (PH) domain and phosphoinositides is a potential anti-cancer strategy.

Purpose of the Study:

• To synthesize novel phosphatidyl inositol mimics as potential Akt inhibitors.
• To evaluate the efficacy of these synthesized compounds in inhibiting Akt activity.
• To identify a lead compound for further development of Akt-targeted cancer therapies.

Main Methods:

• Synthesis of β-glucoside-based phosphatidyl inositol mimics with varying lipophilic and acidic/basic groups.
• Molecular docking studies to predict binding interactions.
• Enzyme-linked immunosorbent assays (ELISA) to measure Akt inhibition.
• Cellular assays in various cancer cell models to assess compound efficacy.

Main Results:

• Several β-glucoside derivatives were synthesized and evaluated as Akt inhibitors.
• Molecular docking and biochemical assays confirmed the inhibitory potential of the synthesized compounds.
• 1-O-octadecanoyl-2-O-β-d-sulfoquinovopyranosyl-sn-glycerol demonstrated the most potent Akt inhibition among the tested compounds.

Conclusions:

• Phosphatidyl inositol mimics based on a β-glucoside scaffold can effectively inhibit Akt.
• The synthesized compound 1-O-octadecanoyl-2-O-β-d-sulfoquinovopyranosyl-sn-glycerol is a promising lead for developing new Akt inhibitors.
• This study provides a foundation for designing novel therapeutics targeting the PI3K-Akt-mTOR pathway in cancer.